Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (191-200 of 499) with videos related to

Pageof 50
Sort By:
British Journal of Cancer|September 11, 2015
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line settingDiether Lambrechts, Bernard Thienpont, Vincent Thuillier, et al.
Journal of Geriatric Oncology|August 16, 2017
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trialPaul Ruff, Eric Van Cutsem, Radek Lakomy, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 22, 2005
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapiesSiegfried Segaert, Josep Tabernero, Olivier Chosidow, et al.
Future Oncology (London, England)|February 16, 2019
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabineMohamad Bassam Sonbol, Daniel H Ahn, David Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerEric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancerEric Van Cutsem, Heinz-Josef Lenz, Claus-Henning Köhne, et al.
Annals of Nuclear Medicine|September 11, 2012
Significant impact of transient deterioration of renal function on dosimetry in PRRTSofie Van Binnebeek, Kristof Baete, Christelle Terwinghe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapySofie Van Binnebeek, Christophe M Deroose, Kristof Baete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2006
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinomaFederico Rojo, Josep Tabernero, Joan Albanell, et al.
Journal of Gastric Cancer|May 2, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.
Pageof 50

Showing results (191-200 of 499) with videos related to

Sort By:
Pageof 50
British Journal of Cancer|September 11, 2015
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line settingDiether Lambrechts, Bernard Thienpont, Vincent Thuillier, et al.
Journal of Geriatric Oncology|August 16, 2017
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trialPaul Ruff, Eric Van Cutsem, Radek Lakomy, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 22, 2005
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapiesSiegfried Segaert, Josep Tabernero, Olivier Chosidow, et al.
Future Oncology (London, England)|February 16, 2019
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabineMohamad Bassam Sonbol, Daniel H Ahn, David Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerEric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancerEric Van Cutsem, Heinz-Josef Lenz, Claus-Henning Köhne, et al.
Annals of Nuclear Medicine|September 11, 2012
Significant impact of transient deterioration of renal function on dosimetry in PRRTSofie Van Binnebeek, Kristof Baete, Christelle Terwinghe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapySofie Van Binnebeek, Christophe M Deroose, Kristof Baete, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2006
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinomaFederico Rojo, Josep Tabernero, Joan Albanell, et al.
Journal of Gastric Cancer|May 2, 2023
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.
Pageof 50